Next-Generation Gene-Editing-Free Universal CAR-T

REVO-U is Wondercel Therapeutics’ proprietary next-generation universal CAR-T platform. By eliminating the need for complex gene editing, REVO-U enables ultra-high-yield manufacturing while maintaining excellent safety and efficacy profiles. This innovative platform represents a significant leap toward making advanced CAR-T therapies more accessible to patients worldwide.

Key Advantages

Ultra-scalable Manufacturing: Produces over 3,000 doses from a single healthy donor batch — comparable to traditional biologic drug production

Significantly Lower Cost: Dramatically reduces cost of goods and removes manufacturing capacity constraints

Enhanced Safety: No graft-versus-host disease (GvHD) observed in early clinical studies

Superior Cell Fitness: Maintains strong expansion and long-term persistence

Proprietary Technologies 

REVO-U integrates multiple breakthrough technologies:

Engineered Armor Receptor: Enhances CAR-T cell survival, persistence, and anti-tumor activity

IMPDH Overexpression: Confers resistance to mycophenolic acid (MPA) through a non-gene-editing approach

Protein-Directed Degradation: Effectively mitigates GvHD risk without gene editing

Early Clinical Validation

In an exploratory study in relapsed/refractory DLBCL, REVO-U demonstrated robust CAR-T expansion, manageable safety profiles, and encouraging efficacy signals. No GvHD was observed across all treated patients. These early results highlight REVO-U’s potential as a transformative off-the-shelf CAR-T solution for both hematologic and solid tumors.